RecruitingNot ApplicableNCT07373236

The Effect of Endogenous GLP-1 on Glucagon Secretion in Type 1 Diabetes

Examining the Effect of Endogenous Glucagon-like Peptide-1 on Glucagon Secretion in Type 1 Diabetes

Sponsor

Asger Lund, MD

Enrollment

12 participants

Start Date

Jan 23, 2026

Study Type

INTERVENTIONAL

Conditions

Type 1 Diabetes

Summary

Type 1 diabetes is a serious and burdensome disease that carries the risk of severe complications and premature death, partly due to low blood sugar, also called hypoglycaemia. This is a constant threat, as individuals with type 1 diabetes lack the body's natural safeguard against low blood sugar: the hormone glucagon, which is normally released from the pancreas. Recent research in mice suggests that this missing safeguard may be due to an imbalance in the hormones released from different cells in the pancreas. More specifically, glucagon-like peptide-1 (GLP-1) appears to play a role in the lack of glucagon secretion. By blocking this hormone using the substance exendin(9-39)NH₂, normalization of glucagon release during low blood sugar has been observed in mice with type 1 diabetes. The present study aims to investigate whether the same mechanism applies in humans with type 1 diabetes. If confirmed, this finding could form the basis for a novel adjunct treatment to insulin therapy and thereby potentially reduce the risk of hypoglycaemia in this patient group.

Eligibility

Sex: MALEMin Age: 18 YearsMax Age: 70 Years

Inclusion Criteria7

Caucasian ethnicity
Age between 18 and 70 years
T1D (diagnosed according to the criteria of the World Health Organization) with HbA1c \<69 mmol/mol (\<8.5%)
Body mass index between 19 and 30 kg/m2
T1D duration of 2-30 years
C-peptide negative (5 gram arginine-stimulated C-peptide ≤100 pmol/l)
Treatment with a stable basal-bolus or insulin pump regimen for ≥3 months

Exclusion Criteria8

Anaemia (haemoglobin below normal range)
Late microvascular complications except mild non-proliferative retinopathy
Liver disease (Evaluated by alanine aminotransferase (ALAT) and/or aspartate aminotransferase (ASAT) \>2 times normal values) or a history of hepatobiliary disorder
Kidney disease (serum creatinine above normal range)
Treatment with any glucose-lowering drugs beside insulin
Active or recent (within 5 years) malignant disease
Regular tobacco smoking or use of other nicotine-containing products
Any condition considered incompatible with participation by the investigators.